3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
88
Neoplasm Metastasis
4
HER2-positive Breast Cancer
4
Stomach Neoplasms
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Hematologic Neoplasms
2
Esophageal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
1
Thyroid Neoplasms
1
Thrombocytosis
1
Sarcoma
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Patient Preference
1
Pathologic Complete Response
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Metastatic HER2-positive Breast Cancer With Brain Metastasis
1
Interventions
Cyclophosphamide
38
Paclitaxel
22
Epirubicin
21
Trastuzumab
20
Docetaxel
20
Doxorubicin
19
Carboplatin
15
Radiotherapy
13
Taxes
11
Filgrastim
11
Neoadjuvant Therapy
9
Bevacizumab
9
Fluorouracil
8
pembrolizumab
7
Tamoxifen
7
Albumin-Bound Paclitaxel
7
Capecitabine
6
pertuzumab
5
Thiotepa
5
Peripheral Blood Stem Cell Transplantation
5
Lapatinib
5
130-nm albumin-bound paclitaxel
5
pegfilgrastim
4
Granulocyte Colony-Stimulating Factor
4
Cisplatin
4
Chemotherapy, Adjuvant
4
Biopsy
4
tipifarnib
3
eribulin
3
Surgical Procedures, Operative
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Inflammatory Breast Neoplasms
×
Ado-Trastuzumab Emtansine
×
Breast
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts